JP7857940B2 - 顆粒球マクロファージコロニー刺激因子の製造 - Google Patents

顆粒球マクロファージコロニー刺激因子の製造

Info

Publication number
JP7857940B2
JP7857940B2 JP2023535012A JP2023535012A JP7857940B2 JP 7857940 B2 JP7857940 B2 JP 7857940B2 JP 2023535012 A JP2023535012 A JP 2023535012A JP 2023535012 A JP2023535012 A JP 2023535012A JP 7857940 B2 JP7857940 B2 JP 7857940B2
Authority
JP
Japan
Prior art keywords
copper
recombinant protein
csf
item
bds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023535012A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553117A (ja
JP2023553117A5 (enExample
Inventor
ミラー、グレッグ
リリー、ショーン
アイアランド、ジェイソン
Original Assignee
パートナー セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パートナー セラピューティクス インコーポレイテッド filed Critical パートナー セラピューティクス インコーポレイテッド
Publication of JP2023553117A publication Critical patent/JP2023553117A/ja
Publication of JP2023553117A5 publication Critical patent/JP2023553117A5/ja
Application granted granted Critical
Publication of JP7857940B2 publication Critical patent/JP7857940B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023535012A 2020-12-08 2021-12-07 顆粒球マクロファージコロニー刺激因子の製造 Active JP7857940B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063122593P 2020-12-08 2020-12-08
US63/122,593 2020-12-08
US202163271444P 2021-10-25 2021-10-25
US63/271,444 2021-10-25
PCT/US2021/062168 WO2022125523A1 (en) 2020-12-08 2021-12-07 Manufacture of granulocyte macrophage-colony stimulating factor

Publications (3)

Publication Number Publication Date
JP2023553117A JP2023553117A (ja) 2023-12-20
JP2023553117A5 JP2023553117A5 (enExample) 2024-12-17
JP7857940B2 true JP7857940B2 (ja) 2026-05-13

Family

ID=81974806

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535012A Active JP7857940B2 (ja) 2020-12-08 2021-12-07 顆粒球マクロファージコロニー刺激因子の製造

Country Status (5)

Country Link
US (1) US20240043486A1 (enExample)
EP (1) EP4259774A4 (enExample)
JP (1) JP7857940B2 (enExample)
CA (1) CA3201327A1 (enExample)
WO (1) WO2022125523A1 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009543560A (ja) 2006-07-14 2009-12-10 ノボザイムス，インコーポレイティド 真菌細胞中の遺伝子発現を上昇させる方法
JP2017500017A (ja) 2013-12-20 2017-01-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
EP1318834A2 (en) * 2000-09-12 2003-06-18 Genetrol Biotherapeutics, Inc. Compositions comprising mixtures of human cytokines and methods of producing the same
WO2006019950A2 (en) * 2004-07-16 2006-02-23 Nektar Therapeutics Al, Corporation Conjugates of a gm-csf moiety and a polymer
CA2903589A1 (en) * 2013-03-15 2014-09-18 Genentech, Inc. Cell culture media and methods of antibody production
CA2942770A1 (en) * 2014-03-23 2015-10-01 Advantech Bioscience Farmaceutica Ltda. Enhancement of recombinant protein expression with copper

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009543560A (ja) 2006-07-14 2009-12-10 ノボザイムス，インコーポレイティド 真菌細胞中の遺伝子発現を上昇させる方法
JP2017500017A (ja) 2013-12-20 2017-01-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bioprocess Biosyst Eng，2007年，30，305-312
Clinical Immunology，2020年，210，108292，https://doi.org/10.1016/j.clim.2019.108292
Partner Therapeutics，Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine in Respiratory Illness in Patients with COVID-19 at Singapore General Hospital，2020年05月，URL:https://partnertx.com/partner-therapeutics-announces-initiation-of-clinical-trial-to-evaluate-leukine-in-respiratory-illness-in-patients-with-covid-19-at-singapore-general-hospital/

Also Published As

Publication number Publication date
JP2023553117A (ja) 2023-12-20
CA3201327A1 (en) 2022-06-16
US20240043486A1 (en) 2024-02-08
WO2022125523A1 (en) 2022-06-16
EP4259774A1 (en) 2023-10-18
EP4259774A4 (en) 2024-12-04

Similar Documents

Publication Publication Date Title
EP2162462B1 (en) A cxc chemokine receptor 4 (cxcr4) antagonistic polypeptide
US20250230210A1 (en) Long-acting granulocyte macrophage-colony stimulating factor
Olsen et al. Expression and characterization of a low molecular weight recombinant human gelatin: development of a substitute for animal-derived gelatin with superior features
WO2018024770A1 (en) Production of biosimilar ustekinumab in cho cells
KR20080027291A (ko) 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법
US20240043486A1 (en) Manufacture of granulocyte macrophage-colony stimulating factor
CN116323659A (zh) 融合多肽
US20080221026A1 (en) Process for manufacture of nematode-extracted anticoagulant protein (NAP)
US12569540B2 (en) Human recombinant hyposialylated erythropoietin, methods of purification and therapeutic uses thereof
WO2022093671A1 (en) Granulocyte macrophage-colony stimulating factor mutants
US20250027067A1 (en) Improved ace2 fusion proteins
PT98538B (pt) Processo de preparacao de factor de crescimento humano epidermico (hegf) dos seus congeneres e de composicoes farmaceuticas que os contem
KR20190129932A (ko) 폐렴구균 감염의 치료 및 예방을 위한 항-폐렴구균 과다면역 글로불린
US20180186838A1 (en) CONOTOXIN PEPTIDE k-CPTX-BTL01, PREPARATION METHOD THEREFOR, AND USES THEREOF
KR101854448B1 (ko) O-당쇄화 된 인간 과립구 대식세포 콜로니 자극 인자
Spraggon et al. Progress in the Design of Immunomodulators Based on the Structure of lnterleukin-1
TW201406394A (zh) 重組靈芝免疫調節蛋白單甲氧基聚乙二醇丙酸琥珀醯亞胺酯修飾物、製備方法和用途
Wang et al. Complementary top-down and bottom up approach for the characterization of G-CSF variants produced from Pichia pastoris
JPH05271280A (ja) 新規ポリペプチド、その製造方法及び該ポリペプチドを 有効成分とする医薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260302

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260331

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260427

R150 Certificate of patent or registration of utility model

Ref document number: 7857940

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150